X
<

What Can Investors Expect from Becton Dickinson in Fiscal 2018?

PART:
1 2 3 4 5
Part 5
What Can Investors Expect from Becton Dickinson in Fiscal 2018? PART 5 OF 5

What Wall Street Thinks about BD after 1Q18 Earnings Release

BD’s latest analyst recommendations

Becton Dickinson (BDX) announced its 1Q18 earnings results on February 6, 2018. It registered robust revenues as well as earnings, exceeding analysts’ estimates. For details, read Becton Dickinson’s Fiscal 1Q18 Results Beat Analyst Estimates. The company also posted its updated fiscal 2018 guidance, which included its recently acquired Bard business as well. In this article, we’ll take a look at the latest analyst recommendations, ratings, and target prices for BD stock for the next one year.

What Wall Street Thinks about BD after 1Q18 Earnings Release

Interested in ABT? Don't miss the next report.

Receive e-mail alerts for new research on ABT

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

As of February 12, 2018, according to a Reuters survey consisting of 19 investment research firms, 63% of analysts recommended BD as a “buy,” and 37% rated it as a “hold.”

Target price

As of February 12, 2018, BD stock has a consensus 12-month target price of $241.58, implying a 12-month return potential of ~11.3% on an investment in BD stock for the next 12 months. BD stock closed at $217.14 on February 9, 2018.

Recent recommendation revisions

Following BD’s 1Q18 earnings results announcement on February 6, 2018, a number of investment brokerages updated their recommendation on BD stock. On February 7, 2018, Morgan Stanley increased its price target on BD stock from $245 to $250. It has an “equal weight” rating on the stock. On February 6, 2018, Piper Jaffray reissued its “overweight” rating on BD stock with a price target of $260 per share.

Peers Medtronic (MDT), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) have average analyst 12-month target prices of $91.98, $243.56, and $68.22, respectively. These target prices imply a 12-month investment return potential of 15.7%, 21.7%, and 19.3%, respectively.

X

Please select a profession that best describes you: